- 1 Fluorosurfactants in groundwater increase the incidence of chronic health conditions among California
- 2 Medicare beneficiaries.
- 3 Lucas M. Neas<sup>a</sup>, William Steinhardt<sup>b</sup>, K. Lloyd Hill<sup>b</sup>, Riley Short<sup>b</sup>, Elaine Hubal, Brian J Reich<sup>c</sup>, Shu Yang<sup>c</sup>,
- 4 Alvin Sheng<sup>c</sup>, Ana G. Rappold<sup>a</sup>
- 5
- 6 Affiliations
- 7 a) Center for Public Health and Environmental Assessment, U.S. Environmental Protection Agency,
- 8 Chapel Hill, North Carolina, USA.
- 9 b) Oak Ridge Associated Universities, Oak Ridge, Tennessee, USA.
- 10 c) Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA.
- 11 Corresponding author: Ana Rappold, U.S. EPA Human Studies Facility, 104 Mason Farm Rd., Chapel Hill,
- 12 NC 27514, USA. E-mail address: rappold.ana@epa.gov (A.G. Rappold).
- 13 Declaration of competing financial interests: This work was funded with internal funds from the U.S.
- 14 Environmental Protection Agency (EPA). The authors declare they have no actual or potential
- 15 competing financial interests.
- 16 Acknowledgments: Although this work has been reviewed for publication by the U.S. Environmental
- 17 Protection Agency, it does not necessarily reflect the views and policies of the Agency. Reference herein
- 18 to any specific commercial products, process, or service by trade name, trademark, manufacturer, or
- 19 otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by
- 20 the United States Government.
- 21 Data sharing: All data used in this manuscript are publicly available from the appropriate data sources.
- 22 Key words: per-and polyfluorinated compounds (PFAS), Medicare, groundwater, hypertension,
- 23 cataracts, chronic kidney disease, chronic obstructive pulmonary disease.

#### 24 Abstract

Background: Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants with emerging
 environmental and regulatory concerns.

- 27 Objectives: This study aimed to estimate the burden of PFAS exposures through ground water on the
- 28 incidence of chronic health conditions among Medicare beneficiaries aged 65 years and older.
- 29 Methods: We estimated PFAS groundwater concentrations for every ZIP code tabulated area (ZCTA) in
- 30 California counties where 25 percent or more of the population's drinking water was derived from
- 31 groundwater. We calculated the annual incidence of non-cancer chronic health conditions among
- 32 1,696,247 Medicare beneficiaries aged 65 and older by residential ZCTA over the seven-year study
- 33 period (2011-2017). A Poisson regression model was used to estimate associations between PFAS
- 34 groundwater concentration and chronic condition incidence with an offset for the number of
- 35 beneficiary-years at risk and adjusting for bias due to non-random sampling of wells, use of groundwater
- 36 for drinking water, demographic characteristics, and lung cancer incidence as a control for smoking.
- 37 Results: Results suggest an association between a 10 ng/L increment in PFAS contaminated
- 38 groundwater and chronic health conditions including hypertension (+1.15%, 95% confidence interval (CI)
- 39 1.01, 1.30), chronic kidney disease (+0.83%, 95% CI 0.68, 0.99) and cataracts (+1.50%, 95% CI 1.35, 1.66).
- 40 Discussion: This small increment in the incidence rate would produce an additional 1,700 new cases of
- 41 hypertension each year in the study population.

Abbreviation	Full Phrase
ZIP-code	Zone Improvement Plan Code
ZCTA	Zip Code Tabulation Area
EPA	Environmental Protection Agency
GAMA	Groundwater Ambient Monitoring and Assessment
ACS-5	American Community Survey
CES	CalEnviroScreen
ЕСНО	Enforcement and Compliance History Online
NLCD	National Land Cover Dataset
POLARIS	Probabilistic Remapping of Soil Survey Geographic Database
PWSID	Public Water System Information Dataset
COPD	Chronic Obstructive Pulmonary Disease
GW	Groundwater
PS	Propensity Score
glm	Generalized Linear Model
XGBoost	Extreme Gradient Boosting
IQR	Inner quartile range
ng/L	nanograms per liter
km	kilometer
m	meter
рН	Potential of Hydrogen
DAG	Directed Acyclic Graph
PFAS	Per- and polyfluoroalkyl sulfonic acids
PFOA	perfluorooctnoic acid
PFOS	perfluoroocane sulfonic acid
PFHXSA	perfluorooctanoic sulfonate
PFHA	perfluorohexanoic acid
PFBSA	perfluorobutanesulfonic
PFBTA	Perfluorobutanoic acid
PFPES	Perfluoropentanesulfonoic acid
PFUNDCA	Perfluoroundecanoic acid
NMEFOSAA	N-Methyl perfluorooctane sulfonamidoacetic acid

42

#### 43 Introduction

44 The rising concern over per- and poly-fluoroalkyl substances (PFAS) in drinking water in the United 45 States has prompted the federal government to identify scientific challenges that must be addressed to 46 understand and address human health impacts (National Science and Technology Council 2023). 47 Potential adverse health effects from PFAS include impacts on fetal development, testicular and kidney 48 cancer, liver tissue damage, suppressed immune function, and cholesterol levels changes (US 49 Environmental Protection Agency 2021). While there is scientific consensus that there are significant 50 health effects associated with perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), 51 the full scope of health effects in the population related to the larger set of PFAS measured in drinking 52 water remains unclear.

53 Recent systematic evidence maps conducted by EPA researchers found limited epidemiological 54 studies on cardiovascular endpoints related to PFAS exposure (Carlson, Angrish et al. 2022, Radke, 55 Wright et al. 2022). Most epidemiological studies focused on acute clinical outcomes, such as heart 56 attack-related hospitalizations, with few examining chronic conditions like hypertension, hyperlipidemia, 57 or type-2 diabetes. These reviews identified few epidemiologic studies of cardiovascular endpoints in 58 cross-sectional studies in the general population and even fewer in cohort studies. Most of these 59 epidemiological studies were of acute clinical endpoints, such as deaths and hospitalizations for 60 myocardial infarctions, and few have examined the effect of exposure on development of chronic health 61 conditions such as the incidence of new diagnoses of major cardiovascular conditions, such as 62 hypertension, hyperlipidemia, or type-2 diabetes.

63 Relative to the widespread use of these chemicals and known health effects, the evidence for 64 population level health burden is still sparse, primarily due to the scarcity of exposure data. Although 65 fluorosurfactants (principally PFOS and PFOA) have been detected in drinking water supplies throughout 66 the US (Hu, Andrews et al. 2016, Guelfo and Adamson 2018), the assessment of the public health 67 burden has been challenging; the exposures have not been systematically measured until recent history 68 and PFAS is not generally measured in water used for consumption such as tap water. Simultaneously, 69 PFAS exposures are both ubiquitous and differential with respect to many known determinants of 70 chronic health conditions, such as income, race, sex, and occupation and there is an extensive lag time 71 between exposure and the development of disease.

72 This study aims to assess the burden of chronic health conditions associated with PFAS exposure in 73 groundwater well sources of drinking water. More specifically, the study estimates the risk associated 74 with the annual incidence of common chronic health conditions among Medicare beneficiaries and 75 identifies outcomes of highest concern for burden assessment at the population level. Propensity scores 76 are employed to account for non-random sampling of wells and non-random use of groundwater for 77 drinking. Additionally, several chronic health conditions are assessed as negative controls to identify 78 potential unmeasured confounding related to smoking, frailty, and social isolation. The analysis 79 quantifies outcomes with strongest association in response to PFAS exposure, the impact of each 80 potential source of bias and offers recommendations for future analytical approaches.

### 81 Methods

To estimate the burden of chronic health conditions associated with PFAS exposure we identified health outcomes from Centers for Medicare and Medicaid Services' Chronic Conditions Warehouse, and exposure levels in groundwater well sources of drinking water. Additionally, areal and well level information about sociodemographic population characteristics, landcover types, and the presence of known and potential PFAS sources were used to control for confounding.

### 87 Health Outcome Data

88 We obtained individual-level information on chronic health conditions among Medicare 89 beneficiaries from the Centers for Medicare and Medicaid Services' Chronic Conditions Warehouse. For 90 each Medicare beneficiary, these annual files provide indicators for 27 chronic health conditions as well 91 as their annually updated ZIP-code of residence (US Department of Health and Human Services 2023). 92 Since Medicare is exceptional for those under 65 years, we restricted our analysis to Medicare

93 beneficiaries aged 65 years and older for whom coverage is nearly universal.

94 The 27 chronic health conditions were separated into nine common conditions (cataract, chronic 95 kidney disease, hypertension, congestive heart failure, hyperlipidemia, anemia, diabetes,

- 96 rheumatoid/osteo arthritis, ischemic heart disease), eight less common conditions (chronic obstructive
- 97 pulmonary disease (COPD), stroke, atrial fibrillations, glaucoma, hyperplasia, acquired hypothyroidism,
- 98 osteoporosis, Alzheimer's, and dementia), and three negative controls (lung cancer, depression, and hip
- 99 fracture). We excluded from the analysis seven outcomes that averaged less than one incident case per
- 100 year in a ZIP code: prostate cancer, breast cancer, endometrial cancer, colorectal cancer, asthma,
- 101 Alzheimer's, and acute myocardial infarction. We used indicators of each chronic health condition to
- 102 calculate the annual incidence of newly diagnosed conditions over the seven-year period (2011-2017)
- 103 for each ZIP code of residence.

For each ZIP code of residence, each unique beneficiary with an incident chronic health condition at any time during the seven-year study period contributed one count to the incidence of the

corresponding condition. Person-years at risk were calculated in a similar manner; for each ZIP code of
 residence, each unique beneficiary contributed a beneficiary-year at risk for every year that they did not
 have the condition as well as the year in which they were first diagnosed.

Medicare beneficiary residential ZIP codes (postal delivery routes assigned by the US Postal Service) were mapped to both ZIP code population weighted centroids (US Department of Housing and Urban Development 2023) and ZIP Code Tabulated Areas (ZCTAs) (US Bureau of the Census 2023). In this process, multiple ZIP codes may have been mapped to the same ZCTA (2,444 ZIP codes were mapped to

- 113 1,756 ZCTAs).
- 114 PFAS Groundwater Concentrations

PFAS concentrations in groundwater were obtained from California's Groundwater Ambient Monitoring and Assessment (GAMA) program, a collaboration between the U.S. Geological Survey and California's State Water Resources Control Board, which began testing domestic and public supply wells for PFAS in 2018 (US Geological Survey 2023). Well location data and PFAS sampling results were downloaded from the GAMA website for the period 2018 until 2021, however most samples were analyzed in recent periods (California Water Boards 2023).

121 Individual wells may have been tested several times for multiple PFAS species and all results were 122 reported in nanograms per liter (ng/L). Values reported as less than the detection limit were interpreted 123 as non-detects and converted to zero before calculating exposure; however, minimum detection limits 124 varied by PFAS testing method. Maximum PFAS concentrations at individual wells were aggregated to 125 the ZCTA-level as an inverse squared distance weighted concentration averaged across all wells within 126 20-km of the ZCTA population centroid, with wells closest to the centroid contributing the most weight.

127

128 Sociodemographic Data

129 Population characteristics, including age, race, and income, were downloaded from the US Census

- Bureau's 5-year American Community Survey (ACS-5) for all ZCTAs and census tracts in California for the
- 131 year 2015 (US Bureau of the Census 2023). Additional sociodemographic data were retrieved from
- 132 California's Office of Environmental Health Hazard Assessment's CalEnviroScreen 4.0 (CES) dataset
- 133 which is an interactive mapping tool and database of environmental, socioeconomic, and public health
- data (California Office of Environmental Health Hazard Assessment 2023). The CES data were available
- by census tract, and for the purpose of the analysis they were averaged for all census tracts within each
- 136 ZCTA as well as linked to the wells found within the census tract.

### 137 PFAS Source

Locations of industries such as airports, fire training facilities, chemical manufacturing sites, and waste management sites registered through USEPA's Enforcement and Compliance History Online (ECHO) database and included in EPA's PFAS Analytics Tools were treated as potential PFAS sources in this study ('PFAS Sources', 23 variables, Table S1) (US Environmental Protection Agency 2023).

- 142 Although, except for most military installations, this dataset does not include any actual data or
- 143 confirmation about each facility's PFAS use or discharge, these industry points are considered to have
- some relevance to PFAS use or discharge. Potential PFAS sources were counted within well site buffers
- 145 (1- and 5-km) and ZCTAs by industry sector, and distances to the nearest PFAS industry source were
- 146 measured from well sites. The number of PFAS industry sources were included as predictors of the 147 exposure and were not considered to be on the pathway between PFAS concentration and health
- 148 outcomes.

## 149 Landcover Data

150 Land use and landcover data were obtained from the Multi-Resolution Land Characteristics 151 Consortium's 2016 National Land Cover Dataset (NLCD) (Dewitz and Survey 2021, Wickham, Stehman et 152 al. 2021). The NLCD uses Landsat imagery to classify landcover into 16 categories at a 30m resolution for 153 the entire US. The NLCD Land Cover Change Index raster dataset, which measures changes in landcover 154 types between 2001-2019, was also included in this analysis. The NLCD also provides a raster of urban 155 imperviousness that assigns each 30m pixel a value of percent developed impervious cover, for example, 156 pavement and rooftops. Landcover data were summarized within California's ZCTAs as well as within 1-157 and 5-km buffers around each well site. Local soil characteristics, including percent organic matter, 158 percent clay, and pH, were summarized at each well site with data from the POLARIS database (Chaney, 159 Wood et al. 2016, Moro Rosso, de Borja Reis et al. 2021). Elevation (meters above sea level) was 160 estimated at each well site using the "elevatr" package in R (Hollister, Shah et al. 2022).

# 161 Statistical approach

162 We used Poisson regression ("glm" package in R) (R Core Team 2022) to model the incidence of chronic health conditions as a function of PFAS concentrations (ng/L) in the groundwater. We first 163 164 restricted study area to regions where at least 25 percent of drinking water was sourced from 165 groundwater wells. This restriction was not based on PFAS groundwater concentrations nor incidence of 166 chronic health conditions. However, to control for potential selection bias and for confounding by 167 common causes introduced by choice of drinking water source we developed a propensity score ('GW 168 PS'). Second, we consider the possibility that wells were not tested at random and may have been 169 differentially sampled with respect to unknown factors. To adjust for selection bias due to preferential 170 sampling of wells, we also developed a well testing propensity score ('Testing PS') defining the 171 probability of a well being tested based on measured covariates. Both propensity scores were included 172 in the model as natural splines with three degrees of freedom.

Additionally, three population-level variables that are known determinants of health were added to

174 the regression ('Regional Determinants of Health'; percent of workforce employed in agriculture,

percent Hispanic ethnicity, and percent with a disability). The prevalence of smoking ('Smoking') was

- 176 unknown, both for the general population and for Medicare beneficiaries. Smoking is known to be the
- 177 overwhelming cause of lung cancer and any contribution of PFAS must be orders of magnitude less, so
- we used lung cancer incidence as a surrogate to account for the unmeasured variation in the prevalence
- 179 of smoking across the ZCTAs in the study area.

Finally, we adjusted for two sets of covariates that may predict the exposure: covariates related to the known and potential sources of PFAS ('PFAS Sources', 23 variables, Table S2) and covariates that were indicative of PFAS concentrations ('PFAS Covariates', 10 variables, Table S2).

183 We also considered depression and hip fracture, as negative controls to assess residual confounding by unknown or omitted sources of confounding. These outcomes have no known biological 184 185 mechanisms that link the incidence of disease to PFAS exposure. However, we expect there may be 186 other factors associated with negative controls and PFAS that are also likely to confound the association 187 with other outcomes of interest. Therefore, the common causes of exposure to PFAS and outcome are 188 hypothesized to be like the common causes of exposure to PFAS and incidence of chronic conditions. 189 These factors may be directly or indirectly measured through variables describing the residential 190 location, type of employment, proximity to sources, demographic characteristics, etc. Since social 191 isolation is the major risk factor for depression, we believe that there exists no biological relationship 192 between PFAS and depression. Any residual association between PFAS and depression would be 193 evidence of residual confounding. We did not find literature reporting a direct link between hip fracture 194 with PFAS exposure. The major risk factor for hip fracture is fall and age, but factors such as arthritis and 195 osteoporosis may contribute to the severity of outcomes associated with hip fracture. Those outcomes 196 are analyzed separately.

# 197 Propensity score for PFAS testing

198 Groundwater wells were not randomly selected for PFAS testing which can potentially lead to 199 selection bias in the analysis. To account for potential selection bias, we estimate the probability of each 200 well being selected for PFAS testing (testing propensity score). We take advantage of the large and 201 comprehensive characterization of residential and potential PFAS sources within 1-km and 5-km radii of each well and use extreme gradient boosting, XGBoost algorithm (Chen and Guestrin 2016), to predict 202 203 the probability of a well being tested for PFAS. More specifically, the following variables were 204 summarized at the well (buffer) level and used in the XGBoost algorithm: the Californian hydrologic 205 region (https://gis.data.ca.gov/datasets/2a572a181e094020bdaeb5203162de15/explore) that the well 206 is in, land use and landcover variables from the NLCD, location of potential industrial PFAS sources (EPA 207 PFAS Analytics Tool), population characteristics (CES and US Census, ACS), soil characteristics (POLARIS), 208 and elevation.

209 The XGBoost model was fit in two stages using the test-set validation approach. The model in the 210 first stage was fit on a random subset containing 90% of wells, with the optimal number of gradient 211 boosting rounds determined via early stopping with ten rounds, using the other 10% of wells as a 212 validation set. That is, the optimal round is the last round after which performance on the validation set 213 doesn't improve for ten rounds. The model in the second stage was then fit on all wells, with the 214 optimal number of rounds found in the first stage. The other parameters of the model are set to the 215 defaults as in the "xgboost" package in R (https://xgboost.readthedocs.io/en/stable/parameter.html). 216 This model was then used to predict propensity scores for all the wells. We aggregated propensities to 217 the ZCTA-level as an inverse distance weighted concentration averaged across all PFAS-tested wells 218 within 20-km of the ZCTA population centroid, as with PFAS concentrations.

### 219 Propensity score for drinking water from ground sources

220 We consider groundwater consumption in the epidemiological model for PFAS in groundwater. 221 While we estimated 22% of Californians rely on groundwater as their primary source of drinking water, 222 this proportion varies considerably by county. In the study area, the overall proportion was 54%. Data 223 on public water systems, including population served and whether sourced from groundwater or surface 224 water, were downloaded from California's Public Water System Information Dataset (PWSID) (California 225 State Water Resources Control Board. 2019). These water-source estimates were combined with 226 estimates of population served by private drinking water wells (Johnson, Belitz et al. 2019) to calculate 227 percent of county population drinking from groundwater. We restricted the study region to ZCTAs with 228 population centroids within the 40 counties where 25% or more of the population rely on groundwater 229 for their drinking water.

230 To account for potential selection bias from restricting our analysis to the specified ZCTAs, we 231 calculate the second propensity score for each ZCTA (probability of selection in the study region). We 232 use extreme gradient boosting (Chen and Guestrin 2016) to calculate the propensity scores, as earlier. 233 However, for the two-stage test-set validation approach, the model was trained on 80% of the ZCTAs 234 and validated on the other 20%; the validation set has a larger proportion to adjust for the smaller 235 number of ZCTAs. We predicted these propensity scores conditional on ZCTA-level variables: land use 236 and landcover variables (NLCD), location of potential industrial PFAS sources (EPA PFAS Analytics Tool), 237 and population characteristics (CES and US Census, ACS).

## 238 Statistical models

239 For each outcome of interest, we fit seven models (M1-M7) for weighted PFAS concentrations as a 240 treatment variable of interest. M1 (Base Model) used the log count of the total Medicare beneficiaries (population-at-risk) as an offset. The subsequent models were cumulative adjustments to the basic 241 242 model: M2 (+ Testing PS) adds the PFAS-well testing propensity score to control for potential selection 243 bias; M3 (+ GW PS) adds the propensity score for the proportion of drinking water from groundwater; 244 M4 (+ Regional Determinants of Health) adds three major regional health determinants for the total 245 population, including percent working in agriculture industry, percent Hispanic and percent with 246 disability; M5 (+ Smoking) adds lung cancer incidence as a surrogate for smoking prevalence. Finally, 247 model M6 (+ PFAS Sources) adds known industrial PFAS sources (Supplemental Table S1) and M7 (+ 248 PFAS Covariates) adds additional covariates (not including sources) that were related to high levels of 249 PFAS (Supplemental Table S2).

250 Sensitivity analysis was conducted with respect to the exposure metric. In addition to the weighted 251 metric used in the main analysis, we also considered unweighted, and propensity weighted metric. The 252 propensity weighted metric was constructed as  $\sum_{i \in D_i} w_i (S_i / p_i) PFAS_i$ , where  $w_i$  is the distance weight 253 of the well to the population centroid of ZCTA,  $S_i$  is the indicator of a sampled location, and  $p_i$  is the 254 propensity score of the sampling and the summation is over sampled locations in  $D_s$ . Rescaling the original propensity score  $p_i = p_i^0/C$ , where  $C = N/(\sum_{i \in D_a} S_i/p_i^0)$  provides a property of 255  $\sum_{i \in D_a} S_i / p_i = N$ . As a result, the constructed propensity weighted metric approximates the weighted 256 average of PFAS had all the wells in the ZCTA  $D_s$  been sampled  $\sum_{i \in D_s} w_i PFAS_i$ . This metric estimates 257 258 the total exposure for this ZCTA and adjusts for preferential sampling by weighting.

Results are reported as the percent difference in the annual incidence of a chronic condition for a 10.0 ng/L increment in estimated PFAS groundwater concentrations, which corresponds to the 80<sup>th</sup> percentile of the PFAS distribution in the study area. To recapitulate, PFAS groundwater concentrations are estimated for each ZCTA as the inverse distance-squared weighted mean of the well-specific maximum PFAS-species concentration for tested wells within 20-km of the ZTCA population centroid.

#### 264 Results

265 The study cohort included 1.7 million Medicare beneficiaries aged 65 years and older living within 266 523 ZCTAs (Figure 1). The greatest reduction in the study cohort was the restriction of the study to 267 beneficiaries residing in California counties with over 25% of their drinking water derived from 268 groundwater, which excluded many of the major urban centers (Figure 1 inset map). Compared to all of 269 California, the population of the study area had greater proportions of Hispanic ancestry, with 270 disabilities and employed in agriculture (Table 1). The study area had a slightly higher incidence of the 271 eight most prevalent chronic health conditions, but a similar incidence of lung cancer, which was used as 272 a proxy for smoking prevalence (Table 1).

273 Among the more than 20,000 wells extracted from the GAMA database, only 2,773 (14%) were 274 tested for PFAS. Statewide, the highest PFAS groundwater concentrations were observed at wells near 275 the most urbanized areas with low groundwater usage for drinking which were not located within the 276 study area (for example, Los Angeles, San Francisco, and San Diego) suggesting that regions less reliant 277 on ground sources of drinking water have more contamination and are tested more often. Within the 278 study area, 1,647 wells were tested for PFAS and 589 (36%) had detectable levels of PFAS, with higher 279 PFAS concentrations observed at wells near or within urban areas (for example, Fresno, Redding, and 280 San Luis Obispo). Although the highest PFAS concentrations were outside the study area, the overall 281 distributions of PFAS concentrations within the study area were remarkably similar to those of 282 California overall (Table 1).

The exposure metric is calculated using the maximum sample at each well regardless of PFAS species. As such, only a handful of the tested PFAS species were represented as the exposure metrics, since 98% of wells' maximum PFAS measurements were from just five species – PFOS, PFHXSA, PFOA, PFHA, and PFBSA (Table S4). These five species are either perfluoroalkyl sulfonic or perfluoroalkyl carboxylic acids with chain lengths ranging from 4 to 8 carbons. Four additional PFAS species (PFBTA, PFPES, PFUNDCA, NMEFOSAA) were also detected in study area wells, but were never the maximum measured species for any well.

290 Based on our analysis of testing propensity, the average probability of a groundwater well being 291 tested for PFAS was 89.1% for wells with detectable levels of PFAS and 83.2% for wells without 292 detectable levels of PFAS, indicating that contaminated wells were more likely to be tested than non-293 contaminated wells. Variables most influential in prediction of well testing were increased land 294 development ("developed, medium-intensity", an NLCD category) within 5-km of the well, presence of 295 1,2,3-trichloropropane (an industrial solvent), decreased levels of chromium 6 and uranium, and shorter 296 distance to national defense industry sites. The presence of PFAS sources explained only 3% of 297 variability  $(R^2)$  in PFAS concentration across wells.

298 The incidences of chronic health conditions were associated with a 10 ng/L increment in PFAS 299 groundwater concentrations with the strongest associations observed for hypertension 1.15% (1.01, 300 1.30), cataract 1.50% (1.35, 1.66), chronic kidney disease 0.83% (0.68, 0.99), and COPD 1.21% (1.01, 301 1.42) for the final covariate model (Table 2, Table S4). Adjustments for PFAS testing propensity and for 302 varying use of groundwater for drinking water produced little change in estimates, but the three 303 regional health covariates and smoking (that is, the ZCTA-specific incidence of lung cancer) were strong 304 confounders as shown by the change in estimates. Ischemic heart disease as a chronic health condition 305 represents a cohort of heart attack survivors and these results suggest that PFAS may have a negative 306 impact on heart attack survival. Adjustments for PFAS sources (23 degrees of freedom) and for other 307 covariates (10 degrees of freedom) showed little evidence of additional confounding although addition 308 of PFAS sources generally increased the effect estimates.

Associations for other non-cancer chronic health conditions generally had small but positive estimated risk, except for asthma and ischemic heart disease (Figure 2). The associations for some outcomes were sensitive to one largest PFAS value observed in Mariposa County. After removing this maximum value, associations between PFAS and anemia, asthma, and diabetes were null. For all other outcomes estimates of risk were consistent and similar in magnitude (Figure S3).

314 Many of these chronic health conditions share common etiologies and these results may reflect 315 shared pathways of action. We performed a mediation analysis to assess whether PFAS associations 316 were mediated by the strong association between PFAS and hypertension, a known risk factor for other 317 chronic health conditions. Hypertension is also the most prevalent condition and has the largest rate of 318 co-occurrence with other conditions. With the addition of hypertension to the model, the PFAS direct 319 effect was reduced to 0.56 (95% Cl 0.40, 0.71) for chronic kidney disease, 0.76 (95% Cl 0.61, 0.92) for 320 cataract, and 0.94 (95% CI 0.73, 1.15) for chronic obstructive pulmonary disease. The proportion of the 321 total effect mediated by hypertension was greatest for cataracts (49%), chronic kidney disease (33%), 322 and chronic obstructive pulmonary disease (22%). These results suggest that hypertension mediated a 323 considerable portion, but not all, of the association between PFAS and these other chronic health 324 conditions.

### 325 Discussion

326 Exposure to PFAS is a national public health concern with a growing need for population level risk 327 assessment. In this study, we characterized the association between PFAS in the groundwater wells and 328 the incidence cases of chronic disease in a large population of Medicare beneficiaries aged 65 years and 329 older residing in California between 2011 and 2017. The study area was a region where approximately 330 54% of population receives drinking water from ground water and the exposure was determined as a 331 distance-weighted mean of the maximum PFAS concentrations at each groundwater well in the postal 332 code of Medicare beneficiaries. We observed the strongest association for the incidence of 333 hypertension, chronic kidney disease, COPD, and cataract; however, the incidence of other chronic 334 diseases (congestive heart failure, stroke, atrial fibrillations, diabetes, glaucoma, osteoarthritis, anemia, 335 acquired hypothyroidism, benign prostatic hyperplasia, and Alzheimer's/dementia) were also positively 336 associated with PFAS exposure.

Incidence of hypertension was increased by one percent (1.15, 95% Cl 1.01, 1.30) for a 10 ng/L
 increment of PFAS. To place this small rate increment in context, the average annual incidence of
 hypertension in the study area was 10.1 percent or about 170,000 new cases of hypertension annually.
 A one percent increase in this rate would add 1,700 additional cases of hypertension each year among

the approximately 1.7 million Medicare beneficiaries in the study area.

342 An association between PFAS and hypertension has been previously reported. Cardiovascular 343 disease has been linked to PFAS by experimental and epidemiologic studies (Meneguzzi, Fava et al. 2021) (Meneguzzi, Fava et al. 2021, Wen, Wang et al. 2022). Hypertension and dyslipidemia have been 344 345 linked to serum PFAS among Norwegian adolescents (Averina, Brox et al. 2021), US women (Ding, 346 Karvonen-Gutierrez et al. 2022) and adolescents (Ma, Xu et al. 2019), and to PFAS drinking water 347 contamination among North Carolina adults (Ward-Caviness, Moyer et al. 2022). Preeclampsia, acute 348 onset hypertension in pregnant women, and other reproductive related outcomes were found to be 349 associated with PFAS in two large systematic reviews (Gao, Ni et al. 2021, Rickard, Rizvi et al. 2022). This 350 study is the first to provide an estimate of the burden of PFAS in groundwater on clinically reported 351 hypertension among a general population aged 65 years and older. An adverse association between 352 PFOS and preeclampsia (acute hypertension in pregnancy) was first reported for women enrolled in a 353 study of a major industrial release of PFAS in the Mid-Ohio River Valley in the United States (Stein, Savitz

et al. 2009, Avanasi, Shin et al. 2016). Adverse associations between PFAS and preeclampsia were also found in Sweden (Rylander, Lindh et al. 2020), Denmark (Birukov, Andersen et al. 2021), Canada (Borghese, Walker et al. 2020), United States (Preston, Hivert et al. 2022) and China (Tian, Zhou et al.

357 2023) but results from a Norwegian cohort were equivocal (Starling, Engel et al. 2014).

358 The results reported here are consistent with a previous study in North Carolina based on 359 electronic health records (Ward-Caviness, Moyer et al. 2022). That study also reported similar 360 associations between presence of any PFAS detected in the drinking water system with hypertension 361 (OR 1.32 (1.15, 1.52)) and chronic kidney disease (OR 1.14 (0.87, 1.51)). In that study, the associations 362 between PFAS and heart failure and diabetes were problematic due to smaller sample size, and cataract 363 and COPD were not considered. Even though both studies were population based, they used different 364 exposure metrics: a binary indicator of any PFAS detected in a water system versus more extensive PFAS 365 testing of groundwater well concentrations.

Two outcomes had negative association with PFAS, asthma and ischemic heart disease. Both outcomes have previously been associated with PFAS but not necessarily in this age group. Here because we identify the outcomes as the incident cases that have occurred for the first time after age 65, we suspect that we may have conditioned on the population that is less likely to be newly diagnosed with these two outcomes, like the healthy survivor bias. More specifically, new incidence of asthma is rare in older adults while ischemic heart disease is diagnosed only in the surviving cases (~75%).

The mediation analysis suggested that hypertension was an important mediator of the PFAS 372 373 association with other chronic health conditions, especially for cataracts and chronic kidney disease but 374 less so for chronic obstructive pulmonary disease. Even after consideration of hypertension, PFAS 375 exposure still showed direct effects on these other conditions suggesting that the PFAS association is not 376 entirely mediated by hypertension. The relationship of hypertension with cataracts and chronic kidney 377 disease has previously been established (Yu, Lyu et al. 2014, Hamrahian and Falkner 2017). The causal 378 relationship between hypertension and chronic obstructive pulmonary disease is more complex as the 379 loss of lung structure may cause hypertension (Kim, Park et al. 2017). Nevertheless, the results of this 380 study indicate that PFAS has a direct association with these chronic health conditions beyond that 381 mediated by hypertension. Ward-Caviness et al. (Ward-Caviness, Moyer et al. 2022) similarly indicated 382 that the health effects of the exposure to PFAS are not specific and may be associated with multiple 383 chronic conditions.

384 Strengths and weaknesses

This study has several strengths and weaknesses. For those over the age 65, Medicare coverage is essentially universal. Thus, data collected on new incidence of chronic disease is representative of the population in the same age group in the study region. A unique strength of Medicare beneficiary summaries is that the chronic diseases are tracked over all beneficiaries and the incidence and prevalence rates can be fully enumerated. Nevertheless, to our knowledge there have not been other studies of PFAS effects using beneficiary files.

391 In this analysis we payed close attention to various sources of potential bias including preferential 392 sampling of PFAS and confounding. We carefully considered selection bias from the non-random 393 sampling of wells for PFAS testing, but the adjustment by a testing propensity score showed minimal 394 impact on the PFAS effect estimates. The restriction of the study area to California counties where more 395 than 25% of drinking water comes from groundwater was also adjusted by a propensity score for 396 groundwater use and several demographic characteristics associated with the selection. The adjustment 397 had minimal impact on the PFAS effect estimates (Table 2), but the reported findings ought not to be 398 extrapolated to areas that were excluded from the analysis. For example, the region around Los Angeles

has a number of wells with detected PFAS levels however, the region is estimated to have low reliance
on the use of ground water sources for drinking. Additionally, some of the outcomes that had the
largest risk estimates, such as cataract, have previously been noted to have both genetic and age
dependent risk factors. Although conceivable that an association exists between average age in
population and average PFAS concentration and that the outcome of interest is a surrogate for age, the
risk estimates did not change after adjusting for age.

405 PFAS sources had a small suppression effect (MacKinnon, Krull et al. 2000), which when added to 406 the model increased the effect estimates across most outcomes. The small explanatory power of PFAS 407 sources suggest that presence of sources cannot act as an Instrumental variable and therefore cannot 408 be a substitute for the direct exposure measurements. However, the addition of these variables can 409 increase the magnitude and improve the overall model.

410 This study is a cross sectional analysis of chronic condition incidence and PFAS exposure in ground 411 water used for drinking water, and as such is subject to several sources of potential confounding. The 412 major confounders in the analysis were the three regional determinants of health (Hispanic ethnicity, 413 disabilities, and agricultural employment) and the incidence of lung cancer as a surrogate for tobacco 414 smoking (Table 2). Adjustment for the three regional variables increased the PFAS associations, while 415 the adjustment for lung cancer reduced these associations. Among other limitations, smoking status of 416 beneficiaries was not available and lung cancer incidence is used to characterize population level rates 417 of smoking. Tobacco smoking does have a strong independent association with hypertension and partial 418 adjustment for smoking using lung cancer incidence shows a large change in estimate, reflecting 419 considerable confounding. The adjustment by the propensity scores for groundwater use showed less 420 evidence of confounding. The widths of the confidence intervals for each chronic condition do not 421 change much across the epidemiologic models (Table 2), providing no evidence of overfitting. This lack 422 of variance inflation persists even for meaningful changes in the point estimates.

423 This study is an ecological study of a shared environmental exposure within the ZIP code of 424 residence. Population level assessments are challenging due the lack of a comprehensive sampling 425 strategy for PFAS. In this study, we used measurements for PFAS in groundwater from GAMA data 426 repository of various sampling campaigns. While possible, measurement errors are unlikely to have 427 varied across ZCTAs differentially with the incidence of chronic health conditions. Similarly, the clinical 428 diagnosis of chronic health conditions supplied by the Medicare data is unlikely to have been influenced 429 by PFAS groundwater concentrations. Finally, temporal misalignment between sampling of PFAS, 430 exposure, and measured outcomes in these early stages of population level investigation is a knowledge 431 gap and should not be overlooked.

432 Future research will benefit from enhanced measurements of PFAS in drinking water sources that is 433 ongoing in many States. In present work we use the best available data on groundwater concentrations, 434 but measures of drinking water exposure are likely to provide direct linkage. We found that adjustment 435 for area-level lung cancer incidence was an important confounder, which implies that smoking is likely 436 to be an important factor for consideration in future studies. The second most influential confounders 437 included areal-level determinants of population health, which in the study area were % hispanic 438 population, % disability, and % employed in agriculture. Adjustment with propensity scores for the non-439 random sampling of wells for PFAS testing and for differences in groundwater use for drinking water 440 produced modest changes in the estimates but are important to consider in studies of ground water 441 exposure. The impact of groundwater use was minimized by our restriction to California counties with 442 at least 25% of drinking water derived from groundwater. Finally, the range of chronic conditions 443 associated with PFAS indicated non-specific modes of action. Separation of PFAS associations into direct

- and indirect effects would be useful in resolving these pathways, as shown by our analysis using
- 445 hypertension as a mediator.
- 446 Conclusion

447 The findings of associations between PFAS in the groundwater and the incidence of hypertension,

- 448 chronic obstructive pulmonary disease, chronic kidney disease, and cataracts among Medicare
- beneficiaries aged 65 years and older are consistent with prior clinical and epidemiologic research and
- 450 are unlikely to be due to confounding, selection bias, or measurement errors. While a small percentage
- 451 increase in annual incidence of clinical hypertension may seem like a small proportion, the impact of
- 452 hypertension on subsequent morbidity and mortality suggests important public health consequences.
- 453

454	References
455	A substitution of the NA Mission D. A. California de M. Dautall (2010). Illuments of France ve
456	Avanasi, K., H. IVI. Shin, V. IVI. Vielra, D. A. Savitz and S. IVI. Bartell (2016). "Impact of Exposure
457 458	Population." <u>Environ Health Perspect</u> <b>124</b> (1): 126-132.
459	Averina, M., J. Brox, S. Huber and A. S. Furberg (2021). "Exposure to perfluoroalkyl substances (PFAS)
460 461	and dyslipidemia, hypertension and obesity in adolescents. The Fit Futures study." <u>Environ Res</u> <b>195</b> : 110740.
462	Birukov, A., L. B. Andersen, M. S. Andersen, J. H. Nielsen, F. Nielsen, H. B. Kyhl, J. S. Jorgensen, P.
463 464	Grandjean, R. Dechend and T. K. Jensen (2021). "Exposure to perfluoroalkyl substances and blood pressure in pregnancy among 1436 women from the Odense Child Cohort." <u>Environ Int</u> <b>151</b> : 106442.
465	Borghese, M. M., M. Walker, M. E. Helewa, W. D. Fraser and T. E. Arbuckle (2020). "Association of
466 467	perfluoroalkyl substances with gestational hypertension and preeclampsia in the MIREC study." <u>Environ</u> Int <b>141</b> : 105789.
468	California Office of Environmental Health Hazard Assessment. (2023). "CalEnviroScreen." from
469	https://oehha.ca.gov/calenviroscreen.
470	California State Water Resources Control Board. (2019). "Drinking water - public water system
471	information. California Open Data." Retrieved August 9, 2019, 2019, from
472	https://data.ca.gov/dataset/drinking-water-public-water-system-information.
473	California Water Boards, S. W. R. C. B. (2023, 5/20/2023). "GAMA DATA DOWNLOADS." from
474	https://gamagroundwater.waterboards.ca.gov/gama/datadownload.
475	Carlson, L. M., M. Angrish, A. V. Shirke, E. G. Radke, B. Schulz, A. Kraft, R. Judson, G. Patlewicz, R. Blain,
476	C. Lin, N. Vetter, C. Lemeris, P. Hartman, H. Hubbard, X. Arzuaga, A. Davis, L. V. Dishaw, I. L. Druwe, H.
477	Hollinger, R. Jones, J. P. Kaiser, L. Lizarraga, P. D. Noyes, M. Taylor, A. J. Shapiro, A. J. Williams and K. A.
478	Thayer (2022). "Systematic Evidence Map for Over One Hundred and Fifty Per- and Polyfluoroalkyl
479	Substances (PFAS)." <u>Environ Health Perspect</u> <b>130</b> (5): 56001.
480	Chaney, N. W., E. F. Wood, A. B. McBratney, J. W. Hempel, T. W. Nauman, C. W. Brungard and N. P.
481	Odgers (2016). "POLARIS: A 30-meter probabilistic soil series map of the contiguous United States."

- 482 Geoderma **274**: 54-67.
- Chen, T. and C. Guestrin (2016). "XGBoost:A scalable Tree Boosting System." <u>Knowledge Discovery in</u>
   <u>Databases</u>: 785-794.
- Dewitz, J. A. and U. G. Survey. (2021). "National Land Cover Database (NLCD) 2019 Products (ver. 2.0,
  June 2021): U.S. Geological Survey data release."

Ding, N., C. A. Karvonen-Gutierrez, B. Mukherjee, A. M. Calafat, S. D. Harlow and S. K. Park (2022). "Perand Polyfluoroalkyl Substances and Incident Hypertension in Multi-Racial/Ethnic Women: The Study of
Women's Health Across the Nation." <u>Hypertension</u> **79**(8): 1876-1886.

- 490 Gao, X., W. Ni, S. Zhu, Y. Wu, Y. Cui, J. Ma, Y. Liu, J. Qiao, Y. Ye, P. Yang, C. Liu and F. Zeng (2021). "Per-
- and polyfluoroalkyl substances exposure during pregnancy and adverse pregnancy and birth outcomes:
- 492 A systematic review and meta-analysis." <u>Environ Res</u> **201**: 111632.
- 493 Guelfo, J. L. and D. T. Adamson (2018). "Evaluation of a national data set for insights into sources,
- 494 composition, and concentrations of per- and polyfluoroalkyl substances (PFASs) in U.S. drinking water."
   495 <u>Environ Pollut</u> 236: 505-513.
- Hamrahian, S. M. and B. Falkner (2017). "Hypertension in Chronic Kidney Disease." <u>Adv Exp Med Biol</u> **956**: 307-325.
- Hollister, J., T. Shah, A. Robitaille, M. Beck and M. Johnson. (2022, 5/30/2023). "elevatr: Access Elevation
  Data from Various APIs." from <u>https://github.com/jhollist/elevatr/</u>.
- 500 Hu, X. C., D. Q. Andrews, A. B. Lindstrom, T. A. Bruton, L. A. Schaider, P. Grandjean, R. Lohmann, C. C.
- 501 Carignan, A. Blum, S. A. Balan, C. P. Higgins and E. M. Sunderland (2016). "Detection of Poly- and
- 502 Perfluoroalkyl Substances (PFASs) in U.S. Drinking Water Linked to Industrial Sites, Military Fire Training
- 503 Areas, and Wastewater Treatment Plants." <u>Environ Sci Technol Lett</u> **3**(10): 344-350.
- Johnson, T. D., K. Belitz and M. A. Lombard (2019). "Estimating domestic well locations and populations
- served in the contiguous US for years 2000 and 2010." <u>Science of the Total Environment</u> 687: 1261 1273.
- 507 Kim, S. H., J. H. Park, J. K. Lee, E. Y. Heo, D. K. Kim and H. S. Chung (2017). "Chronic obstructive
- 508 pulmonary disease is independently associated with hypertension in men: A survey design analysis using 509 nationwide survey data." <u>Medicine (Baltimore)</u> **96**(19): e6826.
- 510 Ma, S., C. Xu, J. Ma, Z. Wang, Y. Zhang, Y. Shu and X. Mo (2019). "Association between perfluoroalkyl 511 substance concentrations and blood pressure in adolescents." <u>Environ Pollut</u> **254**(Pt A): 112971.
- 512 MacKinnon, D. P., J. L. Krull and C. M. Lockwood (2000). "Equivalence of the mediation, confounding and
  513 suppression effect." <u>Prev Sci</u> 1(4): 173-181.
- 514 Meneguzzi, A., C. Fava, M. Castelli and P. Minuz (2021). "Exposure to Perfluoroalkyl Chemicals and
- 515 Cardiovascular Disease: Experimental and Epidemiological Evidence." <u>Front Endocrinol (Lausanne)</u> **12**: 516 706352.
- 517 Moro Rosso, L. H., A. F. de Borja Reis, A. A. Correndo and I. A. Ciampitti (2021). "XPolaris: an R-package 518 to retrieve United States soil data at 30-meter resolution." <u>BMC Res Notes</u> **14**(1): 327.
- 519 National Science and Technology Council (2023). Per- and Polyfloroalkyl Substances (PFAS) Report. I.
- 520 Joint Subcommittee on Environment, and Public Health, Washington, DC, Executive Office of the 521 President of the United States.
- 522 Preston, E. V., M. F. Hivert, A. F. Fleisch, A. M. Calafat, S. K. Sagiv, W. Perng, S. L. Rifas-Shiman, J. E.
- 523 Chavarro, E. Oken, A. R. Zota and T. James-Todd (2022). "Early-pregnancy plasma per- and
- 524 polyfluoroalkyl substance (PFAS) concentrations and hypertensive disorders of pregnancy in the Project
- 525 Viva cohort." <u>Environ Int</u> **165**: 107335.

- R Core Team (2022). R: A Language and Environment for Statistical Computing. Vienna, Austria, R
   Foundation for Statistical Computing.
- Radke, E. G., J. M. Wright, K. Christensen, C. J. Lin, A. E. Goldstone, C. Lemeris and K. A. Thayer (2022).
  "Epidemiology Evidence for Health Effects of 150 per- and Polyfluoroalkyl Substances: A Systematic
  Evidence Map." Environ Health Perspect **130**(9): 96003.
- Rickard, B. P., I. Rizvi and S. E. Fenton (2022). "Per- and poly-fluoroalkyl substances (PFAS) and female
  reproductive outcomes: PFAS elimination, endocrine-mediated effects, and disease." <u>Toxicology</u> 465:
  153031.
- Rylander, L., C. H. Lindh, S. R. Hansson, K. Broberg and K. Kallen (2020). "Per- and Polyfluoroalkyl
   Substances in Early Pregnancy and Risk for Preeclampsia: A Case-Control Study in Southern Sweden."
   <u>Toxics</u> 8(2).
- 537 Starling, A. P., S. M. Engel, D. B. Richardson, D. D. Baird, L. S. Haug, A. M. Stuebe, K. Klungsoyr, Q.
- Harmon, G. Becher, C. Thomsen, A. Sabaredzovic, M. Eggesbo, J. A. Hoppin, G. S. Travlos, R. E. Wilson, L.
- 1. Trogstad, P. Magnus and M. P. Longnecker (2014). "Perfluoroalkyl substances during pregnancy and
- validated preeclampsia among nulliparous women in the Norwegian Mother and Child Cohort Study."
- 541 <u>Am J Epidemiol</u> **179**(7): 824-833.
- 542 Stein, C. R., D. A. Savitz and M. Dougan (2009). "Serum levels of perfluorooctanoic acid and 543 perfluorooctane sulfonate and pregnancy outcome." Am J Epidemiol **170**(7): 837-846.
- 544 Tian, Y., Q. Zhou, L. Zhang, W. Li, S. Yin, F. Li and C. Xu (2023). "In utero exposure to per-/polyfluoroalkyl 545 substances (PFASs): Preeclampsia in pregnancy and low birth weight for neonates." Chemosphere **313**:
- substances (PFASs): Preeclampsia in pregnancy and low birth weight for neonates." <u>Chemosphere</u> **313**:
  137490.
- 547 US Bureau of the Census. (2023). "American Community Survey 5-Year Data (2009-2021)." from 548 <u>https://www.census.gov/data/developers/data-sets/acs-5year.html</u>.
- 549 US Bureau of the Census. (2023). "TIGER/Line Shapefiles." 2023, from
- 550 https://www.census.gov/geographies/mapping-files/time-series/geo/tiger-line-file.html.
- 551 US Department of Health and Human Services. (2023). "Chronic Conditions Data Warehouse." from 552 https://www2.ccwdata.org/web/guest/condition-categories-chronic/.
- 553 US Department of Housing and Urban Development. (2023). "Geospatial Data Storefront." from 554 <u>https://hudgis-hud.opendata.arcgis.com/</u>.
- US Environmental Protection Agency (2021). Announcement of Final Regulatory Determinations for
- 556 Contaminants on the Fourth Drinking Water Contaminant Candidate List. O. o. Water. Federal Register.
  557 86: 12272-12291.
- 558 US Environmental Protection Agency. (2023). "PFAS Analytic Tools." from
- 559 <u>https://awsedap.epa.gov/public/extensions/PFAS\_Tools/PFAS\_Tools.html</u>.

- 560 US Geological Survey. (2023). "Groundwater Ambient Monitoring & Assessment (GAMA)." from
- 561 <u>https://www.usgs.gov/centers/california-water-science-center/science/groundwater-ambient-</u>
- 562 <u>monitoring-assessment-gama</u>.
- 563 Ward-Caviness, C. K., J. Moyer, A. Weaver, R. Devlin and D. Diaz-Sanchez (2022). "Associations between
- PFAS occurrence and multimorbidity as observed in an electronic health record cohort." <u>Environ</u>
   Epidemiol 6(4): e217.
- 566 Wen, X., M. Wang, X. Xu and T. Li (2022). "Exposure to Per- and Polyfluoroalkyl Substances and Mortality 567 in U.S. Adults: A Population-Based Cohort Study." <u>Environ Health Perspect</u> **130**(6): 67007.
- 568 Wickham, J., S. V. Stehman, D. G. Sorenson, L. Gass and J. A. Dewitz (2021). "Thematic accuracy
- assessment of the NLCD 2016 land cover for the conterminous United States." <u>Remote Sensing of</u>
   <u>Environment</u> 257.
- 571 Yu, X., D. Lyu, X. Dong, J. He and K. Yao (2014). "Hypertension and risk of cataract: a meta-analysis." PLoS
- 572 <u>One</u> **9**(12): e114012.
- 573

- Table 1. Characteristics of study area in comparison with all of California: 2011-2017. The study area
- 575 was restricted to California counties where 25% or more of the population's drinking water was supplied
- 576 from groundwater. Unless otherwise specified, results are presented as means and interquartile ranges

577 across Zip Code Tabulation Areas (ZCTA).

Characteristic	All of California	Study Area	
Medicare beneficiaries aged 65 years and older (n)	6,656,235	1,696,247	
ZIP-Code Tabulation Areas (ZCTA) (n)	1,756	523	
Percent of total population			
Using groundwater as drinking source	22	54	
Hispanic ancestry	29.5 (10.2, 43.6)	35.6 (12.4, 56.1)	
Disability	12.9 (8.4, 15.0)	14.3 (9.7, 17.5)	
Agriculture Workers	6.1 (0.3, 5.2)	10.7 (0.9, 13.9)	
Annual incidence of chronic health condition per 100 Medicare beneficiary-years at risk			
Hypertension	8.5 (5.0, 11.1)	10.1 (5.2, 14.3)	
Chronic Obstructive Pulmonary Disease	2.2 (1.2, 2.5)	2.3 (1.5, 2.9)	
Chronic Kidney Disease	3.6 (2.5, 4.2)	3.9 (2.6, 5.0)	
Hyperlipidemia	7.6 (4.5, 10.1)	8.7 (4.5, 12.5)	
Congestive Heart Failure	2.3 (1.6, 2.8)	2.6 (1.7, 3.1)	
Stroke	1.1 (0.8, 1.4)	1.2 (0.8, 1.5)	
Atrial Fibrillation	1.3 (0.9, 1.6)	1.4 (1.0, 1.9)	
Diabetes	3.0 (2.0, 3.6)	3.4 (2.1, 4.4)	
lschemic Heart Disease	3.4 (2.1, 4.1)	3.7 (2.4, 4.7)	
Cataract	5.2 (2.8, 7.1)	5.9 (3.2, 8.4)	
Rheumatoid arthritis / Osteoarthritis	4.5 (2.7, 6.0)	4.9 (3.0, 6.7)	
Anemia	4.6 (3.0, 5.8)	5.0 (3.0, 6.5)	
Acquired Hypothyroidism	2.0 (1.3, 2.5)	2.3 (1.5, 2.9)	
Benign Prostatic Hyperplasia	1.5 (1.0, 1.8)	1.6 (1.0, 2.0)	
Alzheimer's and Dementia	1.6 (1.2, 2.0)	1.7 (1.2, 2.2)	
Asthma	1.0 (0.7, 1.2)	1.1 (0.7, 1.4)	
Depression	2.5 (1.7, 3.1)	2.6 (1.8, 3.4)	
Glaucoma	1.4 (0.95, 1.7)	1.3 (0.83, 1.7)	
Lung cancer	0.30 (0.15, 0.28)	0.25 (0.14, 0.32)	
Hip Fracture	0.39 (0.23, 0.47)	0.41 (0.25, 0.53)	
Testing of groundwater for per- and polyfluoroalkyl substances (PFAS) in wells within 20-km of a ZCTA centroid			
Groundwater wells tested (n)	2,773	1,647	
Groundwater wells with PFAS (n)	1,279	589	
PFAS concentrations in groundwater (ng/L)	11.7 (0.34, 10.7)	9.8 (0.0, 6.9)	

578 Table 2. Estimated percent difference (and 95% confidence intervals) in annual incidence of selected chronic health conditions for a 10 ng/L

579 increment in distance weighted mean of per- and polyfluoroalkyl substances (PFAS) groundwater concentration by epidemiologic model:

580 1,696,247 Medicare beneficiaries over age 65 living in California counties with more than 25% of drinking water from groundwater, 2011-2017.

	Epidemiologic model						
	Base Model	+ Testing PS	+ GW PS	+ Regional Determinants of Health	+ Smoking	+ PFAS Sources	+ PFAS Covariates "Final Model"
Model Degrees of Freedom	2	5	8	11	14	37	47
	0.92	0.66	0.78	2.00	1.12	1.25	1.15
Hypertension	(0.78, 1.07)	(0.51, 0.81)	(0.63, 0.93)	(1.86, 2.14)	(0.99, 1.26)	(1.11, 1.39)	(1.01, 1.30)
Chronic Obstructive	1.40	1.32	1.69	1.87	1.04	1.32	1.21
Pulmonary Disease	(1.2, 1.6)	(1.12, 1.53)	(1.48, 1.9)	(1.67, 2.07)	(0.85, 1.24)	(1.12, 1.53)	(1.01, 1.42)
Chronic Kidnov Disease	0.66	0.59	0.77	1.32	0.73	0.84	0.83
Chronic Kidney Disease	(0.51, 0.82)	(0.44, 0.75)	(0.62, 0.93)	(1.17, 1.47)	(0.58, 0.88)	(0.68, 0.99)	(0.68, 0.99)
Cotoroot	2.37	2.19	1.97	2.52	1.68	1.73	1.50
Cataract	(2.21, 2.53)	(2.02, 2.35)	(1.80, 2.14)	(2.37, 2.68)	(1.53, 1.83)	(1.57, 1.88)	(1.35, 1.66)
Depression	0.43	0.36	0.34	0.58	0.15	0.20	0.09
Depression	(0.24, 0.62)	(0.16, 0.55)	(0.14, 0.54)	(0.39, 0.77)	(-0.04, 0.33)	(0.00, 0.39)	(-0.10, 0.28)
	1.01	1.00	0.99	0.78	0.26	0.34	0.11
HIP Fracture	(0.59, 1.43)	(0.57, 1.43)	(0.56, 1.43)	(0.36, 1.19)	(-0.15, 0.67)	(-0.08, 0.77)	(-0.32, 0.54)

581 Notes:

582 Base model: A conditional Poisson model for incidence of chronic health condition in a Zip Code Tabulation Area (ZCTA) and distance-weighted 583 mean of well-specific maximum PFAS concentration within 20-km of ZCTA population centroid with an offset for beneficiary-years at risk.

+ Testing PS: Previous model with a propensity score (PS) for PFAS testing based on land-use near well.

+ GW PS: Previous model with a propensity score (PS) for county indicators of use of groundwater (GW) for drinking water.

586 + Regional Determinants of Health: Previous model with percent working in agriculture, percent Hispanic, and percent with disability.

587 + Smoking: Previous model plus the incidence of lung cancer as an estimate for smoking prevalence.

+ PFAS Sources: Previous model plus 23 industrial sector-specific counts of PFAS sources in ZCTA (supplemental table S1).

589 + PFAS Covariates: Previous model plus 10 covariates indicative of high PFAS concentrations (supplemental table S2).

- 590 Figure 1. Flow diagram showing restrictions to cohort in number of Medicare beneficiaries and ZIP Code
- 591 Tabulation Areas (ZCTAs) with inset map of California counties showing proportion of population
- supplied with drinking water derived from groundwater: 2011-2017.





594

595 Figure 2. Estimated percent difference in incidence of 19 chronic health conditions for a 10 ng/L

596 increment in distance-weighted mean of per- and polyfluoroalkyl substances (PFAS) groundwater

597 concentration (and 95% confidence intervals) for final epidemiologic model: 1,696,247 Medicare beneficiaries over age 65 living in California counties with more than 25% of drinking water from

598

599 groundwater, 2011-2017.

## **Supplemental Figures and Tables**

## 446 Table S1. List of covariates used in the analysis.

Data Source	Variable		
5-Year American Community	Age, Median		
Survey	Age, Over 65 (%)		
US Census Bureau data accessed	Age, Over 85 (%)		
via 'tidycensus' R Package Downloaded for year 2015	Employed in Agriculture, Forestry, Fishing, Hunting, and Mining (%)		
	Employed in Arts, Entertainment, Recreation, Accommodation, & Food Services (%)		
	Employed in Construction (%)		
	Employed in Educational Services, Health Care, and Social Assistance (%)		
	Employed in Finance, Insurance, Real Estate, Rental, and Leasing (%)		
	Employed in Information (%)		
	Employed in Manufacturing (%)		
	Employed in Other Services, except Public Administration (%)		
	Employed in Professional, Scientific, Management, Administrative, & Waste Mgmt. Services (%)		
	Employed in Public Administration (%)		
	Employed in Retail Trade (%)		
	Employed in Transportation, Warehousing, and Utilities (%)		
	Employed in Wholesale Trade (%)		
	Foreign Born (%)		
	GINI Index of Income Inequality		
	Health Insurance, None (%)		
	Health Insurance, Private (%)		
	Health Insurance, Public (%)		
	Health Insurance, Public, Medicaid (%)		
	Health Insurance, Public, Medicare (%)		
	Health Insurance, Public, VA (%)		
	Hispanic or Latino (%)		
	Households Receiving Food Stamps/SNAP (%)		
	Median Age of Home		
	Median Annual Income (USD)		
	Median Home Value (USD)		
	Median Monthly Rent (USD)		

	Population Living in Owner Occupied Housing (%)
	Population Living in Renter Occupied Housing (%)
	Population Living with a Disability (%)
	Population with Bachelor's Degree or Higher (%)
	Race, American Indian and Alaska Native (%)
	Race, Asian (%)
	Race, Black or African American (%)
	Race, Native Hawaiian and Other Pacific Islander (%)
	Race, Some Other Race (%)
	Race, Two or More Races (%)
	Race, White (%)
	Sex, Female (%)
	Sex, Male (%)
	Total Population
	Unemployment Rate (%)
	Veteran (%)
CalEnviroScreen, v4.0	Asthma
California Office of Environmental	Cardiovascular. Disease
Health Hazard Assessment	CES.4.0.Score
Report published Oct. 2021, data	Cleanup.Sites
downloaded Jun. 2022	Diesel.PM
	Drinking.Water
	Education
	Groundwater. Threats
	HazWaste
	Housing.Burden
	ImpWater.Bodies
	Lead
	Linguistic.lsolation
	Low.Birth.Weight
	Ozone
	Pesticides
	PM2.5
	Pollution.Burden
	Pollution.Burden.Score
	PopChar.

	PopCharScore		
	Poverty		
	Solid.Waste		
	ToxRelease		
	Traffic		
	Unemployment		
Elevation US Geologic Survey data accessed	Elevation at well site (m above sea level)		
	Area burned by wildfire (%)		
National Interagency Fire Center	Area burned by whathe (%)		
(NIFC)	Area burned by wildfire $(m^2)$		
Downloaded Jun. 2022 for years 2008-2017			
NLCD Land Cover Change Index,	Barren Change (%)		
2001-2019	Cultivated Crop Change (%)		
Multi-resolution Land Cover	Forest Change (%)		
Cover Database	Grass and Shrub Change (%)		
Downloaded Jul. 2022	Hay and Pasture Change (%)		
	Herbaceous Wetland Change (%)		
	No Change (%)		
	Urban Change (%)		
	Water Change (%)		
	Within Agricultural Class Change (%)		
	Within Wetland Class Change (%)		
	Woody Wetland Change (%)		
NLCD 2013 Developed			
Imperviousness			
MRLC's National Land Cover	Orban Impervious Cover (%)		
Downloaded Jul. 2022			
NLCD 2013 Land Cover	Barren Land (%)		
Multi-resolution Land Cover	Cultivated Crops (%)		
Consortium (MRLC)'s National Land	Deciduous Forest (%)		
Downloaded for year 2016	Developed, High Intensity (%)		
,	Developed, Low Intensity (%)		
	Developed, Medium Intensity (%)		
	Developed, Open Space (%)		

	Emergent Herbaceous Wetlands (%)
	Evergreen Forest (%)
	Grassland and Herbaceous (%)
	Mixed Forest (%)
	Open Water (%)
	Pasture and Hay (%)
	Perennial Ice and Snow (%)
	Shrub and Scrub (%)
	Woody Wetlands (%)
PFAS Analytics Tools, Industry	Airports
Sectors	Airports (Part 139)
US Environmental Protection	Cement Manufacturing
Agency Data downloaded Aug. 2022	Chemical Manufacturing
	Cleaning Product Manufacturing
	Consumer Products
	Electronics Industry
	Fire Protection
	Fire Training
	Furniture and Carpet
	Glass Products
	Industrial Gas
	Metal Coating
	Metal Machinery Manufacturing
	Mining and Refining
	National Defense
	Oil and Gas
	Paints and Coatings
	Paper Mills and Products
	Petroleum
	Plastics and Resins
	Printing
	Textiles and Leather
	Waste Management
POLARIS Soil Database	Saturated soil hydraulic conductivity (log10cm/hr)
USGS data accessed via 'XPolaris' R	Soil bulk density (g/c³)
package	Soil clay content (%)

Soil organic matter content (log <sub>10</sub> %)
Soil pH
Soil sand content (%)
Soil silt content (%)

447

#### 448 Table S2. Number of PFAS Sources by 23 industrial sectors: California.

Industry Sector	All of California	Study Area
Waste management	2,711	1,183
Oil and gas	624	268
Metal coating	1,724	253
Plastics and resins	954	233
Chemical manufacturing	988	213
Airports	350	185
Electronics industry	2,477	148
Metal machinery manufacturing	716	138
Petroleum	470	122
Printing	829	107
Paints and coatings	463	93
Textiles and leather	506	83
Mining and refining	112	58
Cleaning product manufacturing	316	54
Furniture and carpet	212	48
Paper mills and products	143	41
National defense	175	39
Consumer products	98	30
Fire training	61	30
Cement manufacturing	55	28
Industrial gas	132	25
Glass products	133	17
Airports (part 139)	31	15
Total	14,280	3,411

449

450 Note: EPA's ECHO Database <u>https://awsedap.epa.gov/public/extensions/PFAS\_Tools/PFAS\_Tools.html</u>

## 451 Table S3. Ten ZCTA-level covariates found to be indicative of PFAS concentrations in groundwater.

452

	Chemical	Mean and (Maximum) in ng/L	Number of Wells with PFAS Detected (Number Wells of Tested)	Number of Well Maximums <sup>a</sup>
PFOS	(perfluorooctanoic sulfonate)	11.1 (510.0)	448 (1,646)	269
PFHXSA	(perfluorohexanesulfonic acid)	7.3 (690.0)	447 (1,618)	154
PFOA	(perfluorooctanoic acid)	6.6 (350.0)	407 (1,647)	67
PFHA	(perfluorohexanoic acid)	5.3 (510.0)	359 (1,628)	53
PFBSA	(perfluorobutanesulfonic acid)	3.2 (190.0)	331 (1,618)	36
ADONA	(4,8-dioxa-3H-perfluorononanoic acid)	<0.1 (16.0)	12 (1,257)	8
PFPA	(perfluoropentanoic acid)	0.1 (6.8)	12 (247)	5
6:2FTS	(6:2 fluorotelomer sulfonic acid)	<0.1 (5.9)	3 (247)	3
PFHPA	(perfluoroheptanoic acid)	2.2 (170.0)	241 (1,636)	2
8:2FTS	(8:2 fluorotelomer sulfonic acid)	<0.1 (2.6)	1 (247)	1
NETFOSAA	(N-ethyl perfluorooctane sulfonamidoacetic acid)	<0.1 (6.0)	4 (1,610)	1
PFNA	(perfluorononanoic acid)	0.5 (180.0)	103 (1,636)	1
PFNDCA	(perfluorodecanoic acid)	0.1 (17.0)	42 (1,627)	1

#### 453 Table S4. Summary sampling results for 13 per- and polyfluoroalkyl substances (PFAS) species detected

in groundwater wells within the study area: California, 2018-2021.

<sup>a</sup> Number of wells where this PFAS species had the highest concentration among all sampled species and
thus contributed to the exposure calculations at those wells.

457 Note: the sum of this column (n=601) exceeds the total number of wells in study area (n=589) because

458 12 wells had multiple PFAS compounds tied for the maximum concentration at those wells.

459 Note: Four additional PFAS species (PFBTA, PFPES, PFUNDCA, NMEFOSAA) were detected in some wells,

460 but were never the maximum PFAS species sampled at any well within the study area. Testing occurred

461 for an additional 13 PFAS species (11ClPF3OUDS, 4:2FTS, 9ClPF3ONS, ETFOSA, HFPA-DA, MEFOSA,

462 PFDOA, PFDSA, PFHPSA, PFNS, PFOSA, PFTEDA, PFTRIDA), but all samples in study area were below the

463 minimum detection limit.

Table S4. Estimated percent difference (and 95% confidence intervals) in annual incidence of 17 chronic health conditions for a 10 ng/L

465 increment in distance weighted mean per- and polyfluoroalkyl substances (PFAS) groundwater concentration by epidemiologic model: 1,696,247

466 Medicare beneficiaries over age 65 living in California counties with more than 25% of drinking water from groundwater, 2011-2017.

	Epidemiologic model								
	Base Model	+ Testing PS	+ GW PS	+ Regional Determinants of Health	+ Smoking	+ PFAS Sources	+ PFAS Covariates "Final Model"		
Model Degrees of Freedom	2	5	8	11	14	37	47		
Hypertension	0.92	0.66	0.78	2.00	1.12	1.25	1.15		
	(0.78, 1.07)	(0.51, 0.81)	(0.63, 0.93)	(1.86, 2.14)	(0.99, 1.26)	(1.11, 1.39)	(1.01, 1.30)		
Chronic Obstructive Pulmonary	1.4	1.32	1.69	1.87	1.04	1.32	1.21		
Disorder	(1.2, 1.6)	(1.12, 1.53)	(1.48, 1.9)	(1.67, 2.07)	(0.85, 1.24)	(1.12, 1.53)	(1.01, 1.42)		
Chronic Kidney Disease	0.66	0.59	0.77	1.32	0.73	0.84	0.83		
	(0.51, 0.82)	(0.44, 0.75)	(0.62, 0.93)	(1.17, 1.47)	(0.58, 0.88)	(0.68 <i>,</i> 0.99)	(0.68, 0.99)		
Hyperlipidemia	0.88	0.54	0.45	1.44	0.50	0.65	0.57		
	(0.73, 1.03)	(0.38, 0.69)	(0.29, 0.60)	(1.29, 1.58)	(0.36, 0.64)	(0.51, 0.80)	(0.43, 0.72)		
Congestive Heart Failure	0.51	0.46	0.73	1.11	0.5	0.64	0.51		
	(0.32, 0.7)	(0.26, 0.65)	(0.53, 0.93)	(0.92, 1.3)	(0.31, 0.69)	(0.44, 0.83)	(0.31, 0.7)		
Stroke	0.74	0.64	0.81	1.04	0.54	0.65	0.51		
	(0.48, 1)	(0.37, 0.91)	(0.54, 1.08)	(0.78, 1.3)	(0.28, 0.8)	(0.39, 0.91)	(0.25, 0.78)		
Atrial Fibrillation	1.14	1.12	1.07	1.02	0.43	0.51	0.35		
	(0.9, 1.39)	(0.87, 1.37)	(0.82, 1.32)	(0.78, 1.26)	(0.2, 0.67)	(0.26, 0.75)	(0.1, 0.6)		
Diabetes	-1.03	-1.19	-0.85	0.43	0.06	0.29	0.34		
	(-1.22, -0.83)	(-1.39, 0.99)	(-1.05, -0.65)	(0.23, 0.62)	(-0.13, 0.25)	(0.10, 0.49)	(0.15, 0.54)		
lschemic Heart Disease	-1.22	-1.38	-1.20	-0.44	-0.89	-0.77	-0.79		
	(-1.41, -1.03)	(-1.58, -1.19)	(-1.39, -1.00)	(-0.63, -0.25)	(-1.07, -0.71)	(-0.96, -0.59)	(-0.98, -0.6)		
Cataract	2.37	2.19	1.97	2.52	1.68	1.73	1.50		
	(2.21, 2.53)	(2.02, 2.35)	(1.80, 2.14)	(2.37, 2.68)	(1.53, 1.83)	(1.57, 1.88)	(1.35, 1.66)		
Glaucoma	1.82	1.55	1.26	1.45	0.88	0.76	0.62		
	(1.58, 2.07)	(1.3, 1.81)	(1.01, 1.52)	(1.21, 1.7)	(0.63, 1.12)	(0.5, 1.01)	(0.37, 0.87)		

	I	I	I	I			1
Anemia	0.46	0.35	0.4	0.95	0.3	0.37	0.33
	(0.30, 0.62)	(0.19, 0.51)	(0.24, 0.56)	(0.79, 1.1)	(0.15, 0.45)	(0.22, 0.53)	(0.18, 0.49)
Rheumatoid Arthritis / Osteoarthritis	1.29	1.05	0.93	1.39	0.77	0.81	0.72
	(1.13, 1.45)	(0.89, 1.22)	(0.77, 1.10)	(1.23, 1.55)	(0.62, 0.93)	(0.65, 0.97)	(0.57, 0.88)
Acquired Hypothyroidism	0.94	0.8	0.61	0.72	0.28	0.4	0.5
	(0.73, 1.14)	(0.59, 1.01)	(0.4, 0.83)	(0.52, 0.92)	(0.08, 0.48)	(0.2, 0.61)	(0.29, 0.7)
Chronic Obstructive Pulmonary	1.4	1.32	1.69	1.87	1.04	1.32	1.21
Disorder	(1.2, 1.6)	(1.12, 1.53)	(1.48, 1.9)	(1.67, 2.07)	(0.85, 1.24)	(1.12, 1.53)	(1.01, 1.42)
Alzheimer's and Dementia	0.47	0.48	0.6	0.89	0.48	0.61	0.46
	(0.25, 0.68)	(0.25, 0.7)	(0.38, 0.83)	(0.68, 1.11)	(0.26, 0.69)	(0.39, 0.83)	(0.24, 0.69)
Asthma	-0.56	-0.72	-0.41	0.16	-0.3	-0.16	-0.34
	(-0.86, -0.26)	(-1.02, -0.41)	(-0.72, -0.11)	(-0.14, 0.45)	(-0.58, -0.01)	(-0.46, 0.13)	(-0.63, -0.04)
Benign Prostatic Hyperplasia	0.75	0.52	0.47	0.92	0.44	0.46	0.44
	(0.5, 1)	(0.26, 0.77)	(0.21, 0.72)	(0.67, 1.17)	(0.2, 0.68)	(0.21, 0.71)	(0.19, 0.7)
Depression	0.43	0.36	0.34	0.58	0.15	0.20	0.09
	(0.24, 0.62)	(0.16, 0.55)	(0.14, 0.54)	(0.39, 0.77)	(-0.04, 0.33)	(0.00, 0.39)	(-0.10, 0.28)
Hip Fracture	1.01	1	0.99	0.78	0.26	0.34	0.11
	(0.59, 1.43)	(0.57, 1.43)	(0.56, 1.43)	(0.36, 1.19)	(-0.15, 0.67)	(-0.08, 0.77)	(-0.32, 0.54)

468 Figure S1. Directed Acyclic Graph (DAG) used for development of epidemiologic models.



- 470 Figure S2. Distance-weighted mean of the well-specific maximum per- and polyfluoroalkyl substances (PFAS) concentrations (ng/L) versus 17
- 471 chronic condition incidence rates (%) by study area ZCTAs (n=523): 1,696,247 Medicare beneficiaries over age 65 living in California counties
- 472 with more than 25% of drinking water from groundwater, 2011-2017.
- 473



474 Figure S3. Sensitivity analysis results. Final model results for four chronic conditions split by different per- and polyfluoroalkyl substances (PFAS)

- 475 exposure metrics distance-weighted average of well maximums, distance- and propensity-weighted average of well maximums, and the
- 476 unweighted average of well maximums across ZCTAs in study area without the ZCTA with a single largest PFAS value (n=522): 1,696,247
- 477 Medicare beneficiaries over age 65 living in California counties with more than 25% of drinking water from groundwater, 2011-2017.



478 479